biostudies-literatureUnknown16(23)Patel RR<b>Background:</b> this study aims to evaluate the survival outcomes of patients suffering from head and neck synovial sarcoma (HNSS), especially in relation to patients with a localized disease at diagnosis. <b>Methods:</b> this retrospective chart review includes 57 patients diagnosed with primary HNSS between 1981 and 2020 who presented with a localized disease at diagnosis. Overall survival (OS) from diagnosis, local recurrence-free survival (LRFS), and metastasis-free survival (MFS) from the end of the primary tumor treatment are estimated. The Kaplan-Meier method, the log-rank test, and the Cox proportional hazards regression are used. <b>Results:</b> the 5-year OS, LRFS, and MFS are estimated at 80.4% (95% CI: 66.6%, 88.9%), 67.7% (95% CI: 50.0%, 80.4%), and 50.6% (95% CI: 34.4%, 64Cancers4119https://www.ebi.ac.uk/biostudies/studies/S-EPMC11639992biostudies-literatureOncologic Outcomes in Patients with Localized, Primary Head and Neck Synovial Sarcoma.PMC11639992Lazar AJGoepfert RPLin PPBishop AJAmini BPatel RRBenjamin RSAraujo DMGopalakrishnan VfalseOncologic Outcomes in Patients with Localized, Primary Head and Neck Synovial Sarcoma.<b>Background:</b> this study aims to evaluate the survival outcomes of patients suffering from head and neck synovial sarcoma (HNSS), especially in relation to patients with a localized disease at diagnosis. <b>Methods:</b> this retrospective chart review includes 57 patients diagnosed with primary HNSS between 1981 and 2020 who presented with a localized disease at diagnosis. Overall survival (OS) from diagnosis, local recurrence-free survival (LRFS), and metastasis-free survival (MFS) from the end of the primary tumor treatment are estimated. The Kaplan-Meier method, the log-rank test, and the Cox proportional hazards regression are used. <b>Results:</b> the 5-year OS, LRFS, and MFS are estimated at 80.4% (95% CI: 66.6%, 88.9%), 67.7% (95% CI: 50.0%, 80.4%), and 50.6% (95% CI: 34.4%, 642024-01-01T00:00:00Z2024 Dec2025-04-04T02:54:58.006Z2025-04-04T02:54:58.006ZS-EPMC116399923968230410.3390/cancers16234119